Meeting
2018 ASCO-SITC Clinical Immuno-Oncology Symposium
Real world treatment patterns of first-line combination therapies among BRAF+ metastatic melanoma patients stratified by tumor burden.
Authors
Sameer Ghate
Novartis Pharmaceuticals Corporation, East Hanover, NJ
Sameer Ghate, Jackson Tang, Zhiyi Li, Antonio Reis Nakasato
Disclaimer
This material on this page is ©2024 American Society of Clinical Oncology, all rights reserved. Licensing available upon request. For more information, please contact licensing@asco.org
Poster Details
Session Type
Poster Session
Session Title
Poster Session A
Track
Developmental Therapeutics,Genitourinary Cancer,Head and Neck Cancer,Lung Cancer,Melanoma/Skin Cancers,Gastrointestinal Cancer,Breast and Gynecologic Cancers,Combination Studies,Implications for Patients and Society,Miscellaneous Cancers,Oncolytic Viruses,Hematologic Malignancies
Sub Track
Immune Checkpoints and Stimulatory Receptors
Citation
J Clin Oncol 36, 2018 (suppl 5S; abstr 198)
DOI
10.1200/JCO.2018.36.5_suppl.198
Abstract #
198
Poster Bd #
K7
Abstract Disclosures
Similar Posters
Poster
2018 ASCO-SITC Clinical Immuno-Oncology Symposium
Real world treatment patterns of first-line combination therapies among BRAF+ metastatic melanoma patients.
First Author: Sameer Ghate
Poster
2019 ASCO-SITC Clinical Immuno-Oncology Symposium
Real-world time to next treatment (TTNT) for first-line (1L) targeted and immuno-oncology therapies for BRAF-mutated metastatic melanoma (MM) by lactate dehydrogenase (LDH) level.
First Author: Jason J. Luke
Poster
2023 ASCO Annual Meeting
Real-world treatment patterns and clinical outcomes among subgroups of BRAF-positive metastatic melanoma patients treated with dabrafenib + trametinib.
First Author: Zeynep Eroglu
Poster
2022 ASCO Annual Meeting
Clinical predictors of longer survival in patients with BRAFV600-mutated metastatic melanoma receiving immunotherapy prior to BRAF/MEK inhibition in the metastatic setting.
First Author: Adriana Matutino Kahn